Episode 11 – Interview with Dr. Donald Arnold, lead for the CONCOR-1 trial

Welcome back Rounds Table Listeners!

This week we interview Dr. Donald Arnold, a McMaster University professor and hematologist who is leading the CONCOR-1 trial.

The CONvalescent Plasma for COVID-19 Research Trial (CONCOR-1), is a North American clinical trial designed to evaluate the efficacy and safety of COVID-19 convalescent plasma as a therapy for patients with COVID-19 respiratory illness.

It involves collecting plasma containing neutralizing antibodies from individuals who have recovered from the infection and transfusing it to patients with acute COVID-19 infection.

You can find out more information about the CONCOR-1 trial here:

Questions? Comments? Feedback? We’d love to hear from you.

Leave a Comment

Your email address will not be published. Required fields are marked *

  • Susan Saranchuk says:

    Very Interesting and exciting. Unfortunately, the most I can do for Dr. Arnold is cross my fingers, which I have done. Working while I was listening so I might have missed it, but how long does this study last?

  • Nancy says:

    Great session. So good to learn about Dr. Arnold’s fascinating study.


Michael Fralick

Co-director of the Rounds Table

Michael Fralick is a general internist at Mount Sinai Hospital in Toronto. He completed a Master of Science in Clinical Epidemiology at Harvard University, including a Research Fellowship in Health Policy at the Program On Regulation Therapeutics and Law (PORTAL). His PhD focused on the intersection between machine learning and pharmacoepidemiology.

John Fralick


John Fralick is a general internist at Foothills Medical Centre in Calgary. He completed a Master of Science in Epidemiology at Queen’s University. He completed medical school at the University of Calgary and did his internal medicine training at the University of Toronto.

Donald Arnold


Republish this article

Republish this article on your website under the creative commons licence.

Learn more